As shown in in Figure 5A, patients in the unmarried group show significantly or borderline worse OS prognosis than those in the married group with HR+/HER2– (HR = 1.589, 95% CI: 1.363–1.854, p < 0.001), HR+/HER2 + (HR = 1.851, 95% CI: 1.077–2.321, p = 0.0113), and HR–/HER2– (HR = 1.179, 95% CI: 0.971–1.476, p = 0.084) breast cancers. The gene discussed is ERBB2; the disease is breast cancer.